News Releases

MOUNTAIN VIEW, Calif., Oct. 25, 2017 /PRNewswire/ -- Omnicell, Inc. announced its IV compounding solutions and XT Series Automated Dispensing Cabinets have received 2017 Innovative Technology designations from Vizient, Inc., the largest member-driven healthcare performance improvement company in the country. The designations were based on direct feedback from hospital experts who interacted with Omnicell's IV compounding technology and XT cabinets at the Vizient Innovative Technology Exchange in Denver on September 14, 2017.

The IV compounding solutions and XT Automated Dispensing Cabinets are among the many products that comprise Omnicell's complete platform of solutions for medication and supply management across the continuum of care. The Omnicell portfolio includes IV compounding robotics, medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence systems. Collectively, these solutions support enhanced medication safety and security, help streamline workflows for providers in acute and non-acute care settings, and improve medication adherence.

Omnicell is the only company with a suite of solutions to fully automate IV preparation, including robotic hazardous and nonhazardous IV compounding systems, and workflow solutions. This state-of-the-art technology is augmented by unique data services, applications support, and expertise that enables hospitals and health systems to enhance safety, improve therapy, reduce cost, and facilitate compliance related to sterile compounding processes.

Omnicell^® XT Automated Dispensing Cabinets deliver enhancements in safety, security, and efficiency, with a wide range of configurations available for acute and non-acute care settings. To improve medication management, the XT cabinets feature advanced hardware technology, increased capacity, and smart drawer designs.

"Omnicell continually strives to deliver the most innovative solutions to enable our healthcare partners to maximize safety and quality of care for their patients," said J. Christopher Drew, president, North American Automation and Analytics at Omnicell. "We are especially excited to receive the Innovative Technology Designation, as it is the result of feedback from healthcare experts who understand the value this technology brings to the industry and how it positively impacts patient care."  

"Hospitals and providers are looking for innovations that offer unique and cumulative benefit over other products available on the market today. The feedback on IV compounding technology and XT automated dispensing system by attendees at our Innovative Technology Exchange was strongly in favor of assigning this technology an Innovative Technology designation. Congratulations to Omnicell on receiving this status," said Debbie Archer, director of procurement and Vizient Innovative Technology Program lead. 

Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and represents more than $100 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to review potentially innovative products. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle.

About Vizient, Inc.

Vizient, Inc., the largest member-owned healthcare company in the country, is dedicated to serving members and customers through innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient's diverse membership and customer base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers, and combined this represents almost $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as the recently acquired MedAssets' Spend and Clinical Resource Management (SCM) segment, which includes Sg2. Headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com for more information about the company.

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.

Over 4,000 customers worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety.

Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient adherence to prescriptions, helping to reduce costly hospital readmissions.

Recent Omnicell acquisitions, including Ateb, add distinct capabilities, particularly in central pharmacy, IV robotics, and pharmacy software, creating the broadest medication management product portfolio in the industry.

For more information about Omnicell, Inc. please visit www.omnicell.com.

OMCL-G

SOURCE Omnicell, Inc.